Advantage Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Advantage Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1K	Hold	250	–	–	﹤0.01%	904
2019 Q2	$2K	Hold	250	–	–	﹤0.01%	885
2019 Q1	$2K	Hold	250	–	–	﹤0.01%	876
2018 Q4	$2K	Hold	250	–	–	﹤0.01%	929
2018 Q3	$5K	Hold	250	–	–	﹤0.01%	860
2018 Q2	$6K	Hold	250	–	–	﹤0.01%	752
2018 Q1	$6K	Hold	250	–	–	﹤0.01%	786
2017 Q4	$8K	Hold	250	–	–	﹤0.01%	743
2017 Q3	$5K	Buy	+250	New	+$4.58K	﹤0.01%	831

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Investment Management's ADMS Position: Q3 2019 in Review

Advantage Investment Management held its Adamas Pharmaceuticals (ADMS) position steady in Q3 2019 at 250 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

Advantage Investment Management first reported a position in ADMS in Q3 2017 and has held it in 9 quarters since. The position peaked at $8K in Q4 2017. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

Advantage Investment Management held 250 shares of Adamas Pharmaceuticals worth $1K as of Q3 2019.
Advantage Investment Management left its Adamas Pharmaceuticals share count unchanged in Q3 2019.
Adamas Pharmaceuticals made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #904 holding.
Advantage Investment Management first reported a position in Adamas Pharmaceuticals in Q3 2017 and has held it in 9 quarters since.
Advantage Investment Management's Adamas Pharmaceuticals position peaked at $8K in Q4 2017.
87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.